AbCellera Biologics Inc. Deferred Revenue Recognized
AbCellera Biologics Inc. (ABCL) reported Deferred Revenue Recognized of $3.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-05
- AbCellera Biologics Inc. contract with customer, liability, revenue recognized for the quarter ending 2026-06-30 was $3.70M, a 9.76% decline year-over-year.
- AbCellera Biologics Inc. contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was $7.90M, a 203.85% increase year-over-year.
- AbCellera Biologics Inc. contract with customer, liability, revenue recognized for the quarter ending 2025-09-30 was $8.60M, a 45.76% increase year-over-year.
- AbCellera Biologics Inc. contract with customer, liability, revenue recognized for the quarter ending 2025-06-30 was $4.10M, a 6.82% decline year-over-year.
- AbCellera Biologics Inc. contract with customer, liability, revenue recognized for fiscal 2025 was $11.80M, a 42.72% decline from fiscal 2024.
- AbCellera Biologics Inc. contract with customer, liability, revenue recognized for fiscal 2024 was $20.60M, a 21.18% increase from fiscal 2023.
- AbCellera Biologics Inc. contract with customer, liability, revenue recognized for fiscal 2023 was $17.00M, a 47.83% increase from fiscal 2022.
- AbCellera Biologics Inc. contract with customer, liability, revenue recognized for fiscal 2022 was $11.50M, a 144.68% increase from fiscal 2021.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.70M 10-Q · filed 2026-08-05 | $11.60M 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | $7.90M 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $11.80M 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $8.60M 10-Q · filed 2025-11-06 | $9.50M 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $4.10M 10-Q · filed 2026-08-05 | $4.30M 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | $2.60M 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | $20.60M 10-K · filed 2026-02-24 | |||
| 2024-09-30 | $5.90M 10-Q · filed 2025-11-06 | $18.90M 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $4.40M 10-Q · filed 2025-08-07 | $13.00M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $8.60M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $17.00M 10-K · filed 2026-02-24 | |||
| 2023-09-30 | $4.10M 10-Q · filed 2024-11-04 | $11.00M 10-Q · filed 2024-11-04 | ||
| 2023-06-30 | $4.00M 10-Q · filed 2024-08-06 | $8.10M 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $4.80M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $11.50M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $2.00M 10-Q · filed 2023-11-02 | $9.10M 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | $6.30M 10-Q · filed 2023-08-03 | $7.70M 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $2.70M 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $4.70M 10-K · filed 2024-02-20 | |||
| 2021-09-30 | $1.50M 10-Q · filed 2022-11-08 | $2.30M 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $1.80M 10-Q · filed 2022-08-09 | $3.40M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $1.30M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $3.00M 10-K · filed 2023-02-21 | |||
| 2020-09-30 | $4.00M 10-Q · filed 2021-11-10 | $2.80M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $2.10M 10-Q · filed 2021-08-13 | $5.00M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $1.40M 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | $2.10M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |